Boehringer Increasingly Looking Outside For Oncology Growth
Executive Summary
The private company has stressed home-grown candidates, but it's making more external plays as it builds oncology as one of the pillars of the business.
You may also be interested in...
Deal Watch: Zymeworks Adds Daiichi To List Of Partners In I-O Cross Collaboration
Amgen gets into RNAi for cardiovascular indications with Arrowhead deal. Lilly and J&J out-license preclinical candidates, for epilepsy and cancer respectively, to smaller firms Cerecor and Tracon.
Boehringer Gets Option To Buy ViraTherapeutics And Cancer Virus Therapy
The German pharma agreed to pay up to €210m to investigate ViraTherapeutics' lead candidate, VSV-GP, alone and in combination, with an option to buy ViraTherapeutics depending on the outcome of Phase I studies.
Boehringer’s Oncology Strategy: Build From Niche Lung Cancer Base
With Gilotrif sales building over time, private Boehringer Ingelheim turns its focus to broad development program for its third-generation EGFR inhibitor olmutinib, with ambition to become a leader in lung cancer.